Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.

摘要: Background Preoperative chemotherapy containing anthracyclines and taxanes is well established in early-stage breast cancer. Previous studies have suggested that the sequence may matter but definitive evidence missing. ABCSG trial 34 evaluated activity of MUC1 vaccine tecemotide when added to neoadjuvant treatment; study provided opportunity for second randomisation compare two different anthracycline/taxane sequences. Methods HER2-negative cancer patients were recruited this randomised multicentre Phase 2 study. Patients cohort (n = 311) additionally a conventional or reversed epirubicin/cyclophosphamide docetaxel. Residual burden (RCB) with/without was defined as primary endpoint; RCB groups key secondary endpoint. Results No significant differences terms 0/I (40.1% vs. 37.2%; P 0.61) pathologic complete response (pCR) rates (24.3% 25%, 0.89) observed between reverse sequence. new safety signals reported, upfront docetaxel did not result decreased treatment delay discontinuation. Conclusion Upfront improve tolerability; these results suggest with remains valid option.